Glomerular permselectivity in early stages of overt diabetic nephropathy

被引:0
|
作者
Andersen, S
Blouch, K
Bialek, J
Deckert, M
Parving, HH
Myers, BD
机构
[1] Stanford Univ, Sch Med, Div Nephrol, Dept Med, Stanford, CA 94305 USA
[2] Steno Diabet Ctr, Copenhagen, Denmark
关键词
filtration barrier defect; nephropathic diabetes; proteinuria; ficol; albuminuria; immunoglobulinuria;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Impairment of glomerular size selectivity has been demonstrated by the dextran-sieving technique in nephropathic diabetics with heavy, but not mild proteinuria. The purpose of the present study was to determine whether such a barrier defect could be demonstrated with mild proteinuria by substituting Ficoll 70, a polysucrose, for dextran as a probe of the filtration barrier. Methods. Differential solute clearances were performed in 12 individuals with early diabetic nephropathy on two occasions: after 60 days of treatment with losartan 50 mg daily or a placebo. An uncharged preparation of nonreabsorbable Ficoll 70 was infused along with inulin. Fractional clearance (theta) of Ficoll of discrete size was determined after separating molecules in urine and plasma in narrow 2 Angstrom fractions over a 20 to 60 Angstrom radius interval by size exclusion high-performance liquid chromatography (HPLC). A hydrodynamic theory of hindered ficoll transport through water-filled pores was used to characterize the pore size distribution of the glomerular barrier. Results. The theta for Ficoll molecules with radii >50 Angstrom was selectively enhanced in placebo-treated diabetic nephropathy versus corresponding theta in healthy control subjects (N = 12). Computations revealed a lower distribution of glomerular pores that was unaltered in nephropathic diabetics. However, an upper distribution of large, shunt-like pores was more prominent, exceeding healthy controls by one order of magnitude in diabetic nephropathy (P = 0.01). A trend to lower theta for Ficoll in the 56 to 60 Angstrom radius range during losartan therapy is computed to have lowered the fraction of shunted filtrate by 26 to 44%, depending on whether glomerular pressure declined. The corresponding reduction in theta for endogenous albumin, IgG, and IgG(4) was by 19 to 23% (P < 0.05). Conclusion. Our findings suggest that shunt-like defects, partially reversible by angiotensin II blockade, are present early in the course of diabetic nephropathy. We estimate that such defects can account for immunoglobulinuria in this disorder. Additional impairment of either charge- or shape-selectivity must be invoked to explain the observed level of albuminuria, however.
引用
收藏
页码:2129 / 2137
页数:9
相关论文
共 50 条
  • [31] Albumin and glomerular permselectivity
    Osicka, TM
    Strong, KJ
    Nikolic-Paterson, DJ
    Atkins, RC
    Comper, WD
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (02) : 511 - 512
  • [32] The impact of candesartan treatment on the autoregulation of glomerular filtration rate in hypertensive type 2 diabetic patients without overt nephropathy
    Christensen, PK
    Lund, S
    Parving, LL
    CURRENT HYPERTENSION REPORTS, 2002, 4 (06) : 437 - 438
  • [33] GLOMERULAR RESPONSE TO HYPERGLYCEMIA IN HUMAN DIABETIC NEPHROPATHY
    RUGGENENTI, P
    REMUZZI, A
    VIBERTI, G
    BATTAGLIA, C
    BONETTI, L
    REMUZZI, G
    DIABETOLOGIA, 1989, 32 (07) : A535 - A535
  • [34] ALDOSE REDUCTASE, GLOMERULAR METABOLISM, AND DIABETIC NEPHROPATHY
    COHEN, MP
    METABOLISM-CLINICAL AND EXPERIMENTAL, 1986, 35 (04): : 55 - 59
  • [35] CONTRACTILE GLOMERULAR RESPONSE IN EXPERIMENTAL DIABETIC NEPHROPATHY
    SAIZ, E
    BENITO, A
    RUBIO, MG
    TORRES, MPR
    LUCIO, J
    MARTOS, R
    PUYOL, DR
    NEFROLOGIA, 1994, 14 (04): : 465 - 471
  • [36] Glycosaminoglycans urinary excretion as a marker of the early stages of diabetic nephropathy and the disease progression
    Poplawska-Kita, Anna
    Mierzejewska-Iwanowska, Beata
    Szelachowska, Malgorzata
    Siewko, Katarzyna
    Nikolajuk, Agnieszka
    Kinalska, Ida
    Gorska, Maria
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2008, 24 (04) : 310 - 317
  • [37] GLOMERULAR FUNCTION IN ADVANCED HUMAN DIABETIC NEPHROPATHY
    WINETZ, JA
    GOLBETZ, HV
    SPENCER, RJ
    LEE, JA
    MYERS, BD
    KIDNEY INTERNATIONAL, 1982, 21 (05) : 750 - 756
  • [38] GLOMERULAR BARRIER FUNCTION IN ADVANCED DIABETIC NEPHROPATHY
    MYERS, BD
    ACTA ENDOCRINOLOGICA, 1981, 97 : 36 - 38
  • [39] Research into the glomerular podocyte - is it relevant to diabetic nephropathy?
    White, K. E.
    DIABETIC MEDICINE, 2006, 23 (07) : 715 - 719
  • [40] GLOMERULAR RESPONSE TO HYPERGLYCEMIA IN HUMAN DIABETIC NEPHROPATHY
    REMUZZI, A
    VIBERTI, G
    RUGGENENTI, P
    BATTAGLIA, C
    PAGNI, R
    REMUZZI, G
    AMERICAN JOURNAL OF PHYSIOLOGY, 1990, 259 (04): : F545 - F552